Humoral response to the SARS-CoV-2 vaccine
| . | BCL patients on B-cell–directed treatment <9 mo prior . | BCL patients with no treatment or treatment >9 mo prior . | BCL, TCL, and MM patients receiving other treatments . | HCP at RPCCC and from KSL Inc <65 y of age . | Nursing home residents >65 y of age* . |
|---|---|---|---|---|---|
| . | n = 52 . | n = 25 . | n = 9 . | n = 154 . | n = 47 . |
| IgG production | |||||
| Yes | 6 (11) | 22 (88) | 8 (61.5) | 154 (100) | 43 (91.5) |
| No | 46 (89) | 3 (12) | 1 (38.5) | 0 | 4 (9.5) |
| P† | .00001 | .00001 | .00001 | .00001 | — |
| . | BCL patients on B-cell–directed treatment <9 mo prior . | BCL patients with no treatment or treatment >9 mo prior . | BCL, TCL, and MM patients receiving other treatments . | HCP at RPCCC and from KSL Inc <65 y of age . | Nursing home residents >65 y of age* . |
|---|---|---|---|---|---|
| . | n = 52 . | n = 25 . | n = 9 . | n = 154 . | n = 47 . |
| IgG production | |||||
| Yes | 6 (11) | 22 (88) | 8 (61.5) | 154 (100) | 43 (91.5) |
| No | 46 (89) | 3 (12) | 1 (38.5) | 0 | 4 (9.5) |
| P† | .00001 | .00001 | .00001 | .00001 | — |
IgG titer level above COI threshold: COI ≥ 1.0) in BCL patients on active treatment or within 9 mo after treatment with B-cell–directed therapy vs patients with BCL under observation >9 months after B-cell–directed therapy; vs patients with BCL, TCL, or MM receiving other treatments; vs HCP < 65 y of age; vs nursing home residents > 65 y of age. Data are expressed as the number of patients (percentage of total patients in the study group).
MM, multiple myeloma; TCL, T-cell lymphoma.
Data from KSL Inc.
In comparison with patients with BCL receiving B-cell–directed treatment within 9 mo.